Skip to main content
Premium Trial:

Request an Annual Quote

NantOmics Buys Remaining Shares of OncoPlex Dx

NEW YORK (GenomeWeb) – NantOmics announced today it has acquired the remaining shares of OncoPlex Diagnostics that it didn't already own. 

The terms of the deal were not disclosed. 

NantOmics is a molecular diagnostics firm and part of the NantWorks network of firms founded by Patrick Soon-Shion. His companies have funded OncoPlex since 2008, NantOmics said. 

OncoPlex operates a CAP-accredited and CLIA-certified laboratory in Rockville, Maryland, where the firm is headquartered, and provides mass spectrometry-based tumor profiling services aimed at improving treatment decisions. 

"With this integration, we have added state-of-the-art discovery tools and a complementary array of molecular diagnostic services and tests," Soon-Shiong said in a statement. "More importantly, we have enhanced our ability to deliver patient-specific pan-omic information and, ultimately, improve disease diagnosis and therapy." 

"By combining DNA sequencing, RNA sequencing, and protein expression utilizing mass spectrometry, NantOmics can now offer expanded testing capabilities that provide a broader and more comprehensive picture of a patient's unique tumor biology," OncoPlex CSO Todd Hembrough added.